# BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

> **NCT07492641** · PHASE3 · NOT_YET_RECRUITING · sponsor: **BeOne Medicines** · enrollment: 1056 (estimated)

## Conditions studied

- HR+/HER2- Breast Cancer

## Interventions

- **DRUG:** BGB-43395
- **DRUG:** Letrozole
- **DRUG:** Abemaciclib
- **DRUG:** Palbociclib
- **DRUG:** Ribociclib

## Key facts

- **NCT ID:** NCT07492641
- **Lead sponsor:** BeOne Medicines
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-11
- **Primary completion:** 2029-04
- **Final completion:** 2037-08-07
- **Target enrollment:** 1056 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07492641

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07492641, "BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07492641. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*